Repurposing the FDA-approved drug hydroxyzine pamoate to target the IL-17RB–MLK4 axis in pancreatic cancer

Published: 16 March 2026| Version 1 | DOI: 10.17632/f7hdpx93tm.1
Contributor:
Sui-Chih Tien

Description

Title:The FDA-approved drug hydroxyzine pamoate suppresses pancreatic cancer by disrupting the IL-17RB–MLK4 interaction This dataset contains the raw data, including uncropped Western blot images and fluorescence images.

Files

Institutions

Categories

Drug Development, Pancreatic Cancer

Funders

  • Academia Sinica
    Grant ID: AS-GC-110-MD03, AS-BRTP-115-01

Licence